1. United States of America Stocks

  2. •

    Basic Materials

  3. •

    Agricultural Inputs
Lotus Bio-Technology Development Corp.

Lotus Bio-Technology Development Corp.

LBTD
Lotus Bio-Technology Development Corp.US flagOther OTC
0.01
USD
- -
- -
8.06MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.01
-0.01
- -
- -
-0.01
- -
- -
Free Cash Flow per Basic Share
-0.01
- -
-0.01
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.01
-0.02
- -
- -
-0.01
-0.01
-0.01
Tangible Book Value per Share
-0.01
-0.01
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
5
5
6
181
181
83
83
183
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
-1
- -
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'18
Sep'18
Dec'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
783
Market Capitalization
10
2
4

Working Capital

FRC

•

in mil. unless spec.
Jun'18
Sep'18
Dec'18
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
48.34%
31.89%
Free Cash Flow
- -
39.17%
18.46%
Net Income, GAAP
- -
798.03%
-97.5%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
-0.01
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Hoyt Christopher
Sector
Basic Materials
Industry
Agricultural Inputs
Address
28202 North 58th Street Cave Creek CA United States of America 85331
IPO Date
Apr 22, 2014
CIK
0001520592
Website
lbtdholdings.com
Similar Companies
Hextar Industries Berhad (0161.KL)
Canadian Phosphate Limited (CP8.AX)
Mangalore Chemicals & Fertilizers Limited (MANGCHEFER.NS)
India Pesticides Limited (IPL.BO)
YONFER Agricultural Technology Co., Ltd. (000902.SZ)
TBI Corn Ltd. (TBI.NS)
Business
Lotus Bio-Technology Development Corp. (LBTD) engages in biotechnology research and development, focusing on the production and distribution of bio-fertilizers, bio-pesticides, and related agricultural inputs. The company offers core products including microbial fertilizers under its proprietary brands, organic pesticides derived from natural microorganisms, and soil amendments designed to enhance crop yields and sustainability; it also provides custom formulation services and technical consulting for agribusiness clients. Operations span primarily China with distribution networks in Asia, targeting large-scale farmers, cooperatives, and agricultural enterprises. Founded in 2000 and headquartered in Beijing, China, the company maintains subsidiaries in key provinces for production and R&D facilities. In recent developments, LBTD announced a strategic partnership with a leading Chinese agrotech firm in late 2024 to co-develop next-generation bio-stimulants, alongside securing a CNY 50 million funding round in early 2025 for expanding manufacturing capacity.